1Revenue declined 2.8% to $5.1 million, reflecting the company's continued reliance on non-commercial funding sources such as grants.
2Operating loss widened 52.2% to -$10.2 million, as product candidates in later stages of clinical development generally incur higher costs due to increased trial size and duration.
3Net loss deepened to -$10.2 million, with diluted EPS improving to -$3.98 due to changes in share count, while the company expects to continue incurring significant losses for the foreseeable future.
4Free cash flow was -$7.9 million, with operating cash burn of -$7.8 million, as the company funded clinical development ahead of revenue generation.
5The company is advancing its lead candidate PF614 into a pivotal Phase 3 trial, with future research and development expenses expected to increase significantly upon its full initiation.
6Management explicitly states future viability is dependent on raising additional capital, with no product revenue expected for several years and general and administrative expenses anticipated to increase as headcount grows to support development.